H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $130 from $140 and keeps a Buy rating on the shares. The firm says the initial BNT326 Phase 2 data support the combination of pumitamig plus BNT326.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next
- BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
- District court rules federal limits to vaccines not based on science, NYT says
- BioNTech price target lowered to $94 from $116 at TD Cowen
- BioNTech price target lowered to $125 from $134 at Morgan Stanley